EA
BIIB icon

Euclid Advisors’s Biogen BIIB Stock Holding History

Euclid Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-5,150
Closed -$1.25M – 78
2016
Q2 		$1.25M Sell
5,150
-34,763
-87% -$9.16M 0.05% 314
2016
Q1 		$10.4M Sell
39,913
-13,031
-25% -$3.44M 0.39% 81
2015
Q4 		$16.2M Buy
52,944
+20,544
+63% +$5.9M 0.5% 63
2015
Q3 		$9.46M Sell
32,400
-34,070
-51% -$11.3M 0.43% 70
2015
Q2 		$26.9M Sell
66,470
-47,780
-42% -$19.2M 0.53% 50
2015
Q1 		$48.2M Buy
114,250
+79,450
+228% +$31.3M 0.89% 19
2014
Q4 		$11.8M Sell
34,800
-122,550
-78% -$39.6M 0.11% 181
2014
Q3 		$52.1M Buy
157,350
+510
+0.3% +$168K 0.37% 59
2014
Q2 		$49.5M Sell
156,840
-13,158
-8% -$3.96M 0.35% 66
2014
Q1 		$52M Buy
169,998
+31,560
+23% +$10M 0.39% 52
2013
Q4 		$38.7M Sell
138,438
-11,400
-8% -$2.95M 0.32% 63
2013
Q3 		$36.1M Buy
149,838
+17,693
+13% +$3.96M 0.37% 57
2013
Q2 		$28.4M Buy
+132,145
New +$28.2M 0.36% 62

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Euclid Advisors's BIIB Position: Q3 2016 in Review

Euclid Advisors sold out of Biogen (BIIB) in Q3 2016, closing a stake of 5,150 shares — an estimated $1.25M sold.

Euclid Advisors first reported a position in BIIB in Q2 2013 and held it in 13 quarters. The position peaked at $52.1M in Q3 2014. 1,013 funds tracked by Wall St. Rank hold BIIB as of Q3 2016.

  • Euclid Advisors reported no remaining Biogen position as of Q3 2016 after selling out during the quarter.
  • Euclid Advisors sold 5,150 Biogen shares in Q3 2016, an estimated $1.25M.
  • Euclid Advisors first reported a position in Biogen in Q2 2013 and held it in 13 quarters.
  • Euclid Advisors's Biogen position peaked at $52.1M in Q3 2014.
  • 1,013 funds tracked by Wall St. Rank held Biogen as of Q3 2016.

Based on Euclid Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.